Sight Sciences, Inc.: peers
Sight Sciences, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Sight Sciences, Inc., NeuroPace, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Sight Sciences, Inc.base SGHT · 🇺🇸 US Percentile in Healthcare Percentile in USA | NeuroPace, Inc. NPCE · 🇺🇸 US Percentile in Healthcare Percentile in USA | Delcath Systems, Inc. DCTH · 🇺🇸 US Percentile in Healthcare Percentile in USA | 908 Devices Inc. MASS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Orthofix Medical Inc. OFIX · 🇺🇸 US Percentile in Healthcare Percentile in USA | CapsoVision, Inc. CV · 🇺🇸 US Percentile in Healthcare Percentile in USA | Tactile Systems Technology, Inc. TCMD · 🇺🇸 US Percentile in Healthcare Percentile in USA | OrthoPediatrics Corp. KIDS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $448 MAug 1, 2026 · Market data6th of 8 | $487 MSep 18, 2026 · Market data5th of 8 | $500 MOct 20, 2026 · Market data4th of 8 | $503 MOct 14, 2026 · Market data3rd of 8 | $377 MOct 15, 2026 · Market data7th of 8 | $372 MOct 30, 2026 · Market data8th of 8 | $545 MOct 30, 2026 · Market data2nd of 8 | $573 MOct 19, 2026 · Market data1st of 8 | $494 M8 ranked |
| Revenue (Better neither way: ranked highest first) | $77 MFY2025 · SEC6th of 8 | $100 MFY2025 · SEC4th of 8 | $85 MFY2025 · SEC5th of 8 | $56 MFY2025 · SEC7th of 8 | $822 MFY2025 · SEC1st of 8 | $14 MFY2025 · SEC8th of 8 | $330 MFY2025 · SEC2nd of 8 | $236 MFY2025 · SEC3rd of 8 | $93 M8 ranked |
| Net income (Higher is better) | $-38 MFY2025 · SEC6th of 8 | $-21 MFY2025 · SEC4th of 8 | $3 MFY2025 · SEC3rd of 8 | $19 MFY2025 · SEC1st of 8 | $-92 MFY2025 · SEC8th of 8 | $-25 MFY2025 · SEC5th of 8 | $19 MFY2025 · SEC2nd of 8 | $-40 MFY2025 · SEC7th of 8 | $-23 M8 ranked |
| Employees (Better neither way: ranked highest first) | 186December 31, 2025 · Profile4th of 7 | 209December 31, 2025 · Profile2nd of 7 | 156February 13, 2026 · Profile5th of 7 | 96As on September 2020 · Profile7th of 7 | —— | 99December 31, 2025 · Profile6th of 7 | 988As on 2021 · Profile1st of 7 | 203As on 2022 · Profile3rd of 7 | 1867 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | -3.1%FY2025 · SEC8th of 820th21st | +25.1%FY2025 · SEC2nd of 873rd83rd | +129.1%FY2025 · SEC1st of 894th97th | +17.7%FY2025 · SEC3rd of 864th75th | +2.9%FY2025 · SEC7th of 832nd38th | +15.2%FY2025 · SEC5th of 859th71st | +12.5%FY2025 · SEC6th of 855th67th | +15.4%FY2025 · SEC4th of 860th72nd | +15.3%8 ranked |
| Revenue growth, 3 years a year (Higher is better) | +2.7%FY2025 · SEC7th of 735th43rd | +30.0%FY2025 · SEC2nd of 781st91st | +215.3%FY2025 · SEC1st of 799th100th | +6.3%FY2025 · SEC6th of 746th57th | +21.3%FY2025 · SEC4th of 773rd86th | ———— | +10.1%FY2025 · SEC5th of 753rd70th | +24.6%FY2025 · SEC3rd of 777th88th | +21.3%7 ranked |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | +17.1%FY2025 · SEConly one with it60th60th | ———— | +17.1%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | 86.2%FY2025 · SEC1st of 887th95th | 77.2%FY2025 · SEC3rd of 878th89th | 86.2%FY2025 · SEC2nd of 887th95th | 50.6%FY2025 · SEC8th of 837th64th | 68.8%FY2025 · SEC6th of 866th81st | 52.9%FY2025 · SEC7th of 840th66th | 75.9%FY2025 · SEC4th of 876th88th | 73.0%FY2025 · SEC5th of 871st85th | 74.5%8 ranked |
| Operating margin (Higher is better) | -48.0%FY2025 · SEC6th of 832nd15th | -16.3%FY2025 · SEC4th of 843rd23rd | 0.8%FY2025 · SEC2nd of 859th42nd | -70.1%FY2025 · SEC7th of 827th13th | -9.9%FY2025 · SEC3rd of 849th28th | -188.3%FY2025 · SEC8th of 816th6th | 8.9%FY2025 · SEC1st of 871st65th | -16.6%FY2025 · SEC5th of 843rd23rd | -16.5%8 ranked |
| Net margin (Higher is better) | -49.7%FY2025 · SEC7th of 832nd15th | -21.5%FY2025 · SEC6th of 842nd21st | 3.2%FY2025 · SEC3rd of 867th55th | 34.7%FY2025 · SEC1st of 896th96th | -11.2%FY2025 · SEC4th of 847th26th | -186.9%FY2025 · SEC8th of 816th7th | 5.8%FY2025 · SEC2nd of 871st64th | -16.8%FY2025 · SEC5th of 844th23rd | -14.0%8 ranked |
| Free cash flow margin (Higher is better) | -38.7%FY2025 · SEC6th of 830th13th | -11.3%FY2025 · SEC5th of 842nd21st | 24.6%FY2025 · SEC1st of 893rd93rd | -43.9%FY2025 · SEC7th of 828th13th | -0.2%FY2025 · SEC3rd of 852nd34th | -169.4%FY2025 · SEC8th of 817th5th | 12.3%FY2025 · SEC2nd of 875th75th | -6.8%FY2025 · SEC4th of 844th24th | -9.0%8 ranked |
| Return on equity (Higher is better) | -50.8%FY2025 · SEC6th of 743rd18th | -158.7%FY2025 · SEC7th of 715th7th | 3.0%FY2025 · SEC3rd of 775th47th | 15.1%FY2025 · SEC1st of 787th78th | -19.3%FY2025 · SEC5th of 760th28th | ———— | 8.8%FY2025 · SEC2nd of 780th61st | -11.3%FY2025 · SEC4th of 766th32nd | -11.3%7 ranked |
| Return on invested capital (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | 13.2%FY2025 · SEConly one with it56th59th | ———— | 13.2%— |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | 75.2×price Oct 20, 2026 · Market data1st of 283rd92nd | ———— | ———— | ———— | 22.9×price Oct 30, 2026 · Market data2nd of 238th60th | ———— | 49.0×2 ranked |
| Price to sales (Better neither way: ranked highest first) | 5.1׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 4.8׆price Sep 18, 2026 · Market datanot ranked: old priceold priceold price | 4.5×price Oct 20, 2026 · Market data3rd of 655th74th | 7.6×price Oct 14, 2026 · Market data2nd of 667th85th | 0.5×price Oct 15, 2026 · Market data6th of 67th14th | 26.8×price Oct 30, 2026 · Market data1st of 687th95th | 1.5×price Oct 30, 2026 · Market data5th of 625th40th | 2.2×price Oct 19, 2026 · Market data4th of 636th51st | 3.4×6 ranked |
| Price to book (Better neither way: ranked highest first) | 7.0׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 25.6׆price Sep 18, 2026 · Market datanot ranked: old priceold priceold price | 4.5×price Oct 20, 2026 · Market data2nd of 664th74th | 3.5×price Oct 14, 2026 · Market data3rd of 656th67th | 0.8×price Oct 15, 2026 · Market data6th of 616th16th | 28.1×price Oct 30, 2026 · Market data1st of 695th97th | 2.5×price Oct 30, 2026 · Market data4th of 643rd56th | 1.6×price Oct 19, 2026 · Market data5th of 634th40th | 3.0×6 ranked |
| Free cash flow yield (Higher is better) | -6.7%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -2.3%†price Sep 18, 2026 · Market datanot ranked: old priceold priceold price | 4.2%price Oct 20, 2026 · Market data2nd of 684th61st | -4.9%price Oct 14, 2026 · Market data5th of 655th27th | -0.3%price Oct 15, 2026 · Market data3rd of 667th36th | -6.2%price Oct 30, 2026 · Market data6th of 651st25th | 7.4%price Oct 30, 2026 · Market data1st of 692nd78th | -2.8%price Oct 19, 2026 · Market data4th of 660th30th | -1.6%6 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | 0.7×FY2025 · SEC4th of 562nd53rd | 3.1×FY2025 · SEC5th of 592nd91st | ———— | ———— | 0.3×FY2025 · SEC3rd of 543rd34th | ———— | 0.0×FY2025 · SEC1st of 54th3rd | 0.3×FY2025 · SEC2nd of 539th31st | 0.3×5 ranked |
| Net debt to EBITDA (Lower is better) | ———— | ———— | ———— | ———— | ———— | ———— | -2.3×FY2025 · SEConly one with it7th4th | ———— | -2.3×— |
| Interest cover (Higher is better) | -7.2×FY2025 · SEConly one with it49th26th | ———— | ———— | ———— | ———— | ———— | ———— | ———— | -7.2×— |
| Piotroski F-score (Higher is better) | 5 of 9FY2025 · SEC1st of 4 | 5 of 9FY2025 · SEC1st of 4 | —— | —— | 5 of 9FY2025 · SEC1st of 4 | —— | —— | 4 of 9FY2025 · SEC4th of 4 | 5.0 of 94 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 4 of 18FY2025 · Scorecard8th of 8 | 7 of 18FY2025 · Scorecard5th of 8 | 11 of 21FY2025 · Scorecard2nd of 8 | 10 of 20FY2025 · Scorecard4th of 8 | 8 of 21FY2025 · Scorecard6th of 8 | 3 of 11FY2025 · Scorecard7th of 8 | 21 of 26FY2025 · Scorecard1st of 8 | 11 of 21FY2025 · Scorecard2nd of 8 | 44% passed8 ranked |
| Valuation checks (Higher is better) | —— | —— | 0 of 5FY2025 · Scorecard4th of 6 | 0 of 5FY2025 · Scorecard4th of 6 | 2 of 5FY2025 · Scorecard2nd of 6 | 0 of 5FY2025 · Scorecard4th of 6 | 4 of 6FY2025 · Scorecard1st of 6 | 2 of 5FY2025 · Scorecard2nd of 6 | 20% passed6 ranked |
| Growth checks (Higher is better) | 0 of 6FY2025 · Scorecard8th of 8 | 5 of 6FY2025 · Scorecard2nd of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 5 of 6FY2025 · Scorecard2nd of 8 | 4 of 6FY2025 · Scorecard5th of 8 | 1 of 2FY2025 · Scorecard7th of 8 | 5 of 6FY2025 · Scorecard2nd of 8 | 4 of 6FY2025 · Scorecard5th of 8 | 75% passed8 ranked |
| Profitability checks (Higher is better) | 1 of 5FY2025 · Scorecard4th of 8 | 1 of 5FY2025 · Scorecard4th of 8 | 3 of 5FY2025 · Scorecard2nd of 8 | 3 of 5FY2025 · Scorecard2nd of 8 | 0 of 5FY2025 · Scorecard7th of 8 | 0 of 2FY2025 · Scorecard7th of 8 | 4 of 6FY2025 · Scorecard1st of 8 | 1 of 5FY2025 · Scorecard4th of 8 | 20% passed8 ranked |
| Financial health checks (Higher is better) | 3 of 6FY2025 · Scorecard6th of 8 | 1 of 4FY2025 · Scorecard8th of 8 | 2 of 3FY2025 · Scorecard4th of 8 | 2 of 3FY2025 · Scorecard4th of 8 | 2 of 4FY2025 · Scorecard6th of 8 | 2 of 2FY2025 · Scorecard1st of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 3 of 4FY2025 · Scorecard3rd of 8 | 67% passed8 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecard4th of 7 | 0 of 3FY2025 · Scorecard4th of 7 | 1 of 3FY2025 · Scorecard3rd of 7 | 0 of 1FY2025 · Scorecard4th of 7 | 0 of 1FY2025 · Scorecard4th of 7 | —— | 3 of 3FY2025 · Scorecard1st of 7 | 1 of 1FY2025 · Scorecard1st of 7 | 0% passed7 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 41.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 77.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 59.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 88.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 96.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 11.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 101.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 66.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 71.9%8 ranked |
| Institutions holding (Better neither way: ranked highest first) | 1312026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 1052026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 1452026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 1232026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 1362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 502026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 1622026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 1412026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 1348 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | -1.1 pp2026-Q2 against 2026-Q1 · 13F6th of 8 | -1.2 pp2026-Q2 against 2026-Q1 · 13F7th of 8 | +2.9 pp2026-Q2 against 2026-Q1 · 13F2nd of 8 | -4.6 pp2026-Q2 against 2026-Q1 · 13F8th of 8 | +4.9 pp2026-Q2 against 2026-Q1 · 13F1st of 8 | +2.2 pp2026-Q2 against 2026-Q1 · 13F3rd of 8 | +1.4 pp2026-Q2 against 2026-Q1 · 13F4th of 8 | +0.8 pp2026-Q2 against 2026-Q1 · 13F5th of 8 | +1.1 pp8 ranked |
| Dividends | |||||||||
| Shareholder yield (Higher is better) | ———— | 10.2%†FY2025 · SECnot ranked: old priceold priceold price | 1.2%FY2025 · SEC2nd of 235th24th | ———— | ———— | ———— | 4.9%FY2025 · SEC1st of 276th67th | ———— | 3.0%2 ranked |
| Dividend per share (Better neither way: ranked highest first) | —— | $0.00FY2025 · SEConly one with it | —— | —— | —— | —— | —— | —— | $0.00— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Sight Sciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; NeuroPace, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Delcath Systems, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; 908 Devices Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Orthofix Medical Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CapsoVision, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Tactile Systems Technology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; OrthoPediatrics Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Sight Sciences, Inc. | -48.0%FY2025 | 32nd percentile in Healthcaremedian -7.8%, 678 companies | 15th percentile in USAmedian 3.4%, 2,607 companies |
| NeuroPace, Inc. | -16.3%FY2025 | 43rd percentile in Healthcaremedian -7.8%, 678 companies | 23rd percentile in USAmedian 3.4%, 2,607 companies |
| Delcath Systems, Inc. | 0.8%FY2025 | 59th percentile in Healthcaremedian -7.8%, 678 companies | 42nd percentile in USAmedian 3.4%, 2,607 companies |
| 908 Devices Inc. | -70.1%FY2025 | 27th percentile in Healthcaremedian -7.8%, 678 companies | 13th percentile in USAmedian 3.4%, 2,607 companies |
| Orthofix Medical Inc. | -9.9%FY2025 | 49th percentile in Healthcaremedian -7.8%, 678 companies | 28th percentile in USAmedian 3.4%, 2,607 companies |
| CapsoVision, Inc. | -188.3%FY2025 | 16th percentile in Healthcaremedian -7.8%, 678 companies | 6th percentile in USAmedian 3.4%, 2,607 companies |
| Tactile Systems Technology, Inc. | 8.9%FY2025 | 71st percentile in Healthcaremedian -7.8%, 678 companies | 65th percentile in USAmedian 3.4%, 2,607 companies |
| OrthoPediatrics Corp. | -16.6%FY2025 | 43rd percentile in Healthcaremedian -7.8%, 678 companies | 23rd percentile in USAmedian 3.4%, 2,607 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Sight Sciences, Inc. | NeuroPace, Inc. | Delcath Systems, Inc. | 908 Devices Inc. | Orthofix Medical Inc. | CapsoVision, Inc. | Tactile Systems Technology, Inc. | OrthoPediatrics Corp. |
|---|---|---|---|---|---|---|---|---|
| 2025 | $77 MSEC6th | $100 MSEC4th | $85 MSEC5th | $56 MSEC7th | $822 MSEC1st | $14 MSEC8th | $330 MSEC2nd | $236 MSEC3rd |
| 2024 | $80 MSEC5th | $80 MSEC4th | $37 MSEC7th | $48 MSEC6th | $799 MSEC1st | $12 MSEC8th | $293 MSEC2nd | $205 MSEC3rd |
| 2023 | $81 MSEC4th | $65 MSEC5th | $2 MSEC7th | $50 MSEC6th | $747 MSEC1st | — | $274 MSEC2nd | $149 MSEC3rd |
| 2022 | $71 MSEC4th | $46 MSEC6th | $3 MSEC7th | $47 MSEC5th | $461 MSEC1st | — | $247 MSEC2nd | $122 MSEC3rd |
| 2021 | $49 MSEC4th | $45 MSEC5th | $4 MSEC7th | $42 MSEC6th | $464 MSEC1st | — | $208 MSEC2nd | $98 MSEC3rd |
| 2020 | $28 MSEC5th | $41 MSEC4th | — | $27 MSEC6th | $407 MSEC1st | — | $187 MSEC2nd | $71 MSEC3rd |
| 2019 | — | — | — | — | $460 MSEC1st | — | $189 MSEC2nd | $73 MSEC3rd |
| 2018 | — | — | — | — | $453 MSEC1st | — | $144 MSEC2nd | $58 MSEC3rd |
| 2017 | — | — | $3 MSEC4th | — | $434 MSEC1st | — | $109 MSEC2nd | $46 MSEC3rd |
| 2016 | — | — | $2 MSEC4th | — | $410 MSEC1st | — | $85 MSEC2nd | $37 MSEC3rd |
| 2015 | — | — | $2 MSEC4th | — | $396 MSEC1st | — | $63 MSEC2nd | $31 MSEC3rd |
| 2014 | — | — | $1 MSEC3rd | — | $402 MSEC1st | — | $48 MSEC2nd | — |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Sight Sciences, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- NeuroPace, Inc.NPCE · 🇺🇸 USASame industry: Medical Devices · Similar size: $487 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $487 M (Sep 18, 2026) · revenue $100 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Delcath Systems, Inc.DCTH · 🇺🇸 USASame industry: Medical Devices · Similar size: $500 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $500 M (Oct 20, 2026) · revenue $85 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- 908 Devices Inc.MASS · 🇺🇸 USASame industry: Medical Devices · Similar size: $503 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $503 M (Oct 14, 2026) · revenue $56 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Orthofix Medical Inc.OFIX · 🇺🇸 USASame industry: Medical Devices · Similar size: $377 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $377 M (Oct 15, 2026) · revenue $822 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- CapsoVision, Inc.CV · 🇺🇸 USASame industry: Medical Devices · Similar size: $372 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $372 M (Oct 30, 2026) · revenue $14 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Tactile Systems Technology, Inc.TCMD · 🇺🇸 USASame industry: Medical Devices · Similar size: $545 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $545 M (Oct 30, 2026) · revenue $330 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- OrthoPediatrics Corp.KIDS · 🇺🇸 USASame industry: Medical Devices · Similar size: $573 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $573 M (Oct 19, 2026) · revenue $236 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- ClearPoint Neuro, Inc.CLPT · 🇺🇸 USASame industry: Medical Devices · Similar size: $296 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $297 M (Oct 22, 2026) · revenue $37 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- MiMedx Group, Inc.MDXG · 🇺🇸 USASame industry: Medical Devices · Similar size: $684 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $684 M (Oct 14, 2026) · revenue $419 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Treace Medical Concepts, Inc.TMCI · 🇺🇸 USASame industry: Medical Devices · Similar size: $280 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $280 M (Oct 26, 2026) · revenue $213 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Artivion, Inc.AORT · 🇺🇸 USASame industry: Medical Devices · Similar size: $739 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $739 M (Oct 30, 2026) · revenue $441 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Cytek Biosciences, Inc.CTKB · 🇺🇸 USASame industry: Medical Devices · Similar size: $770 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $770 M (Oct 27, 2026) · revenue $201 M (year to December 2025)96 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.